FDA’s Neoadjuvant Breast Cancer Accelerated Approval Pathway Starts To Take Shape
Executive Summary
The agency is stressing that its new neoadjuvant pathway is intended for areas of high unmet need and won’t become the path of least resistance for pharma. But it is also signaling openness for testing drugs aimed at women with HER2-positive disease, who have a better prognosis and treatment options.
You may also be interested in...
Revised pCR Guidance Likely To Include Failed ALTTO Trial, FDA Says
Oncology office director Pazdur says whole data package supporting accelerated approval in neoadjuvant breast cancer of Roche’s Perjeta was far stronger than the data for GSK’s Tykerb, which just failed in ALTTO. FDA is standing by use of pCR as a surrogate endpoint but says only a select group of drugs will qualify.
Revised pCR Guidance Likely To Include Failed ALTTO Trial, FDA Says
Oncology office director Pazdur says whole data package supporting accelerated approval in neoadjuvant breast cancer of Roche’s Perjeta was far stronger than the data for GSK’s Tykerb, which just failed in ALTTO. FDA is standing by use of pCR as a surrogate endpoint but says only a select group of drugs will qualify.
FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial
FDA draft guidance lays out use of pathologic complete response to support accelerated approval of drugs for women with high-risk, early-stage breast cancer. Pathway allows for initial approval based on one pivotal study, which could be extended to assess survival and confirm clearance.